CH Sud Francilien Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2011
NCT01757587
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Sud Francilien | CH Sud Francilien

Active Ingredients

Drugs in Phase 4 Trials (1)

vildagliptin (1 trial)

Drugs in Other Trials (2)

remifentanil (ultiva) (1 trial)

sufentanil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3